ADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor, leading to a significant drop in its stock price [1]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company that specializes in manufacturing, marketing, and developing specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [1]. Group 2: Recent Developments - On October 9, 2024, ADMA Biologics announced the surprise resignation of its independent outside auditor, CohnReznick LLP, which triggered a sharp decline in its stock price [1]. - The stock price of ADMA Biologics fell by more than 20% during trading on October 10, 2024, following the announcement [1]. Group 3: Legal Implications - Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential legal actions related to the stock drop, encouraging affected investors to seek additional information and consider their legal options [2].